Literature DB >> 7497593

Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.

A Johnsson1, C Olsson, O Nygren, M Nilsson, B Seiving, E Cavallin-Stahl.   

Abstract

The pharmacokinetics of platinum (Pt) and cisplatin (CDDP)-DNA adducts were studied in nude mice after single-dose CDDP treatments. Whole blood, serum, kidney, lever, testis, brain, and tumor were collected at different intervals after injection of CDP at different dose levels. Pt was measured with flameless atomic absorption spectrometry (FAAS) or adsorptive voltammetry (AdV) and CDDP-DNA adducts with quantitative immunohistochemistry. The drug was immediately absorbed into the blood circulation (peak serum Pt levels were reached within 5 min) after i.p. CDDP administration, and distribution into most tissues also occurred rapidly (tissue Pt levels peaked at 15 min). With a sampling period of 7 days there was a biphasic elimination of Pt from blood, serum, and tissues. In the brain the pharmacokinetics differed with a gradual accumulation of Pt occurring during the 1st week. Formation of CDDP-DNA adducts in tissues was a slower process, with maximal levels being achieved at between 30 min and 4 h after drug administration, followed by a steady state lasting for at least 24 h. Each tissue type had its specific immunohistochemical staining pattern of adducts. With escalating CDDP doses there was a linear, or almost linear, increase in Pt concentrations and CDDP-DNA adduct levels in all sample types examined. These results suggest that a fair estimation of the amount of drug in tumor and normal tissues can be made from analysis of serum Pt at a fixed time point after a single dose of CDDP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7497593     DOI: 10.1007/bf00685625

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  39 in total

1.  Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.

Authors:  C R Nichols; S D Williams; P J Loehrer; F A Greco; E D Crawford; J Weetlaufer; M E Miller; A Bartolucci; L Schacter; L H Einhorn
Journal:  J Clin Oncol       Date:  1991-07       Impact factor: 44.544

2.  Optical microscope system for standardized cell measurements and analyses.

Authors:  J W Bacus; L J Grace
Journal:  Appl Opt       Date:  1987-08-15       Impact factor: 1.980

3.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

Authors:  J B Vermorken; W J van der Vijgh; I Klein; A A Hart; H E Gall; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1984-03

4.  Distribution of cisplatin in tumor-free versus tumor-bearing B6D2F1 mice.

Authors:  R Amlacher; V Böckel; A Mackowiak; M Stadeler; D Frankenberg; H Hoffmann
Journal:  Arch Geschwulstforsch       Date:  1990

5.  Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.

Authors:  P M Terheggen; B G Floot; E Scherer; A C Begg; A M Fichtinger-Schepman; L den Engelse
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

6.  Cis-diamminedichloroplatinum (II)-procaine pharmacokinetic interaction in mice bearing P388 leukemia.

Authors:  M Esposito; M O Vannozzi; M Viale; C Pellecchia; F Merlo; A Cadoni; S Cafaggi; B Parodi; R Lerza; M C Poirier
Journal:  Anticancer Res       Date:  1993 Sep-Oct       Impact factor: 2.480

7.  Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans.

Authors:  J Uozumi; T Ueda; T Yasumasu; Y Koikawa; S Naito; J Kumazawa; K Sueishi
Journal:  Int Urol Nephrol       Date:  1993       Impact factor: 2.370

8.  cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.

Authors:  E Reed; C L Litterst; C C Thill; S H Yuspa; M C Poirier
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

9.  Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.

Authors:  A B Campbell; S M Kalman; C Jacobs
Journal:  Cancer Treat Rep       Date:  1983-02

10.  Differential actions of cisplatin on renal proximal tubule and inner medullary collecting duct cells.

Authors:  H R Brady; M L Zeidel; B C Kone; G Giebisch; S R Gullans
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

View more
  22 in total

1.  Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.

Authors:  Julie L Eiseman; Jan H Beumer; Lora H Rigatti; Sandra Strychor; Kelly Meyers; Samuel Dienel; Charles C Horn
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-15       Impact factor: 3.333

2.  Platinum compounds for high-resolution in vivo cancer imaging.

Authors:  Miles A Miller; Bjorn Askevold; Katherine S Yang; Rainer H Kohler; Ralph Weissleder
Journal:  ChemMedChem       Date:  2014-02-06       Impact factor: 3.466

3.  Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.

Authors:  P Bergström; A Johnsson; T Bergenheim; R Henriksson
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

4.  Cisplatin and 4-hexylresorcinol synergise to decrease metastasis and increase survival rate in an oral mucosal melanoma xenograft model: a preliminary study.

Authors:  Sang-Woon Lee; Seong-Gon Kim; Young-Wook Park; Haeyong Kweon; Jwa-Young Kim; Horatiu Rotaru
Journal:  Tumour Biol       Date:  2013-02-15

5.  Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.

Authors:  Ramindhu Galgamuwa; Kristine Hardy; Jane E Dahlstrom; Anneke C Blackburn; Elize Wium; Melissa Rooke; Jean Y Cappello; Padmaja Tummala; Hardip R Patel; Aaron Chuah; Luyang Tian; Linda McMorrow; Philip G Board; Angelo Theodoratos
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

Review 6.  Circadian clock control of the cellular response to DNA damage.

Authors:  Aziz Sancar; Laura A Lindsey-Boltz; Tae-Hong Kang; Joyce T Reardon; Jin Hyup Lee; Nuri Ozturk
Journal:  FEBS Lett       Date:  2010-03-15       Impact factor: 4.124

7.  Carbon nanotube capsules enhance the in vivo efficacy of cisplatin.

Authors:  Adem Guven; Gabriel J Villares; Susan G Hilsenbeck; Alaina Lewis; John D Landua; Lacey E Dobrolecki; Lon J Wilson; Michael T Lewis
Journal:  Acta Biomater       Date:  2017-05-02       Impact factor: 8.947

8.  Toxicity and pharmacokinetics of isolated lung perfusion with cisplatin in rat.

Authors:  Y Kaneda; D Liu; A Brooks; A Abolhoda; D Labow; M E Burt; R J Ginsberg
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-07

9.  DNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies.

Authors:  Qi-En Wang
Journal:  World J Biol Chem       Date:  2015-08-26

10.  Tumor Static Concentration Curves in Combination Therapy.

Authors:  Tim Cardilin; Joachim Almquist; Mats Jirstrand; Alexandre Sostelly; Christiane Amendt; Samer El Bawab; Johan Gabrielsson
Journal:  AAPS J       Date:  2016-09-28       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.